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Approximately 4 million neonatal deaths 
occur each year globally, of which more than 
one-quarter are caused by preterm birth 
(Lawn et al. 2005). Although 99% of neo-
natal deaths arise in low- or medium-income 
countries, preterm birth has also emerged as a 
public health priority in the United States and 
other industrialized nations. The U.S. rates of 
preterm birth have increased by > 30% since 
1981 and by 18% since 1990, and as of 2004 
accounted for 12.8% of live births (Martin 
et al. 2008). Preterm birth is associated with 
more than one-third of infant deaths in the 
United States, making it the leading cause of 
neona  tal mortality (Mathews et al. 2004). In 
addition, many complications from preterm 
birth develop into chronic health conditions 
such as blindness, deafness, cerebral palsy, and 
lower IQ (Slattery and Morrison 2002).
There is growing concern for the potential 
role of environmental pollutants in preterm 
birth, yet this area remains poorly understood 
(Institute of Medicine 2006). Only a few envi-
ronmental agents have been investigated for 
associations with preterm birth in well-con-
trolled epidemiologic studies, including the 
insecticide DDT (dichlorodiphenyltrichloro-
ethane) (Longnecker et al. 2001), secondhand 
tobacco smoke (Jaakkola et al. 2001; Kharrazi 
et al. 2004), and lead (Andrews et al. 1994). 
There is further evidence for the contribu-
tion of environmental exposures on preterm 
birth through observations of increased risk 
among individuals with polymorphisms in 
genes involved in xenobiotic metabolism 
(Nesin 2007).
Phthalates are a group of chemicals used 
in a wide range of industrial applications and 
consumer products, and this widespread use 
results in exposure among most of the gen-
eral population (Hauser and Calafat 2005; 
Silva et al. 2004). Sources of exposure to low-
molecular-weight phthalates [e.g., diethyl 
phthalate and di-n-butyl phthalate (DBP)] 
may include personal care products such as 
perfumes, lotions, and cosmetics; through 
their use as solvents; or as coatings on timed-
release pharmaceuticals (Hauser and Calafat 
2005). Exposure to higher-molecular-weight 
phthalates such as di(2-ethylhexyl) phthalate 
(DEHP) and butylbenzyl phthalate (BBzP) 
may be related to their use as plasticizers 
in flexible vinyl plastic consumer products 
(e.g., construction materials, floor covering, 
and vinyl wall paper), food packaging, and 
medical devices (Hauser and Calafat 2005). 
Exposure to DEHP was associated with 
decreased gestational age in studies conducted 
in Italy (Latini et al. 2003) and in New York 
City (Whyatt et al. 2008). Conversely, a dif-
ferent study conducted in New York City 
reported a positive association between ges-
tational age and urinary concentrations of 
metabolites of DEHP as well as the phthalate 
metabolites mono-n-butyl phthalate (MBP) 
and monoethyl phthalate (MEP) (Wolff 
et al. 2008).
Although previous studies investigated 
the association between phthalate exposure 
and gestational age among primarily term 
births, the relationship with preterm births 
has not yet been addressed. In the present 
study we conducted a nested case–control 
analysis of the association between urinary 
phthalate metabolites and preterm birth in a 
Mexico City birth cohort.
Materials and Methods
Study population. The present study was nested 
within a Mexican birth cohort study in which 
women were recruited during prenatal visits at 
one of four clinics of the Mexican Institute of 
Social Security (IMSS) in Mexico City between 
2001 and 2003 (Ettinger et al. 2009). The clin-
ics serve a low- to moderate-income population. 
Women were eligible if they had a confirmed 
pregnancy of no more than 14 weeks’ gesta-
tion, did not present with a high-risk pregnancy 
(including daily consumption of alcoholic bev-
erages; addiction to illegal drugs; continuous 
use of prescription drugs; or diagnosis of mul-
tiple pregnancy, preeclampsia, renal or heart 
disease, gestational diabetes, or seizures that 
require medical treatment), planned to reside 
in Mexico City for approximately 5 years, and 
were willing to participate in a follow-up study 
protocol. Gestational length was estimated by 
maternal recall of the date of last menstrual 
period, because early ultrasound is not routinely 
performed at the IMSS clinics. Information on 
demographic, socioeconomic, and other factors 
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that could confound the relationship between 
phthalate exposure and gestational length was 
collected through questionnaire. The study was 
described in detail to all participating moth-
ers, and all study participants gave informed 
consent. The research protocol was approved 
by the Ethics and Research Committees 
of all participating institutions. The involve-
ment of the Centers for Disease Control and 
Prevention (CDC) laboratory was limited 
and was determined not to constitute engage-
ment in human subjects research. Of the 1,853 
women approached, 670 (36%) agreed to par-
ticipate in the cohort study. Of these, archived 
third-trimester urine samples were available for 
518 nonsmoking women because urine col-
lection did not commence until after the ini-
tiation of study recruitment had begun. In the 
present nested case–control study conducted 
within these 518 women, 30 cases were selected 
randomly among 44 women who delivered 
before the completion of 37 weeks of gesta-
tion. Controls (n = 30) were selected randomly 
among women who had completed ≥ 37 weeks 
of gestation at the time of delivery.
Phthalate metabolites in urine. A spot (sec-
ond morning void) urine sample was collected 
from each woman during a third-  trimester visit 
to the project’s research center. Phthalate metab-
olites were measured in urine to avoid potential 
sample contamination from the parent diester 
and because the metabolites, as opposed to the 
parent diesters, seem to be the active toxicants 
(Li et al. 1998; Peck and Albro 1982). The fol-
lowing 11 phthalate metabolites were measured 
at the CDC (Atlanta, GA, USA): mono(2-
ethylhexyl) phthalate (MEHP), monobenzyl 
phthalate (MBzP), MBP, MEP, mono-isobutyl 
phthalate (MiBP), three oxidized metabolites 
of DEHP [mono(2-ethyl-5-hydroxyhexyl) 
phthalate (MEHHP), mono(2-ethyl-5-ox-
ohexyl) phthalate (MEOHP), and mono(2-
ethyl-5-carboxypentyl) phthalate (MECPP)], 
mono(3-carboxypropyl) phthalate [MCPP; an 
oxidized metabolite of both DBP and di-n-octyl 
phthalate (DOP)], and monocarboxyisooctyl 
phthalate (MCOP) and monocarboxyisononyl 
phthalate (MCNP) (oxidized metabolites of 
diisononyl phthalate and diisodecyl phthalate, 
respectively). 
The analytical approach involved enzy-
matic deconjugation of the metabolites from 
their glucuronidated form, solid-phase extrac-
tion, separation with high-performance liquid 
chromatography, and detection by isotope-di-
lution tandem mass spectrometry (Silva et al. 
2007). The limits of detection (LODs) were 
in the low nanogram per milliliter range for 
each phthalate metabolite. Isotopically labeled 
internal standards and conjugated internal 
standards were used to increase precision of 
measurements. Along with the unknown sam-
ples, each analytical run included calibration 
standards, reagent blanks, and quality control 
materials of high and low concentration to 
monitor for accuracy and precision. Analysts 
at the CDC were blind to all information 
concerning subjects. 
Urinary phthalate metabolite concentra-
tions were corrected for urine dilution by 
specific gravity (SG) using the formula Pc 
= P[(1.014 – 1)/SG – 1)], where Pc is the 
SG-corrected phthalate metabolite concentra-
tion (micrograms per liter), P is the observed 
phthalate metabolite concentration, 1.014 
is the median SG value among the present 
study population, and SG is the specific grav-
ity of the individual urine sample. SG was 
measured using a handheld digital refrac-
tometer (ATAGO Company Ltd., Tokyo, 
Japan). Phthalate metabolite concentrations 
were also corrected by creatinine (Cr; phtha-
late metabolite concentrations expressed as 
micrograms per gram Cr), which was mea-
sured using a MicroLab AT Plus robotic 
liquid handler (Hamilton Co., Reno, NV, 
USA) and Microplate Spectrophotometer 
(SpectraMax 340; Molecular Devices, 
Sunnyvale, CA, USA). Finally, we calculated 
(in nanomoles per milliliter) the sum of con-
centrations of DEHP metabolites that were 
measured (i.e., MEHP, MEHHP, MEOHP, 
and MECPP).
Statistical analysis. We performed data 
analysis using SAS version 9.1 (SAS Institute 
Inc., Cary, NC, USA). Maternal and preg-
nancy characteristics were tabulated and 
compared between cases and controls using 
Student’s t-tests and chi-square tests when 
appropriate. For phthalate metabolite concen-
trations below the LOD, we used an imputed 
value equal to one-half the LOD. In prelimi-
nary crude analyses to assess whether women 
who experienced a preterm birth had higher 
phthalate metabolite concentrations than 
controls, we compared geometric mean values 
between the two groups using t-tests. To take 
into account potential confounding variables, 
we used multivariable logistic regression to 
model the odds of having high (above the 
median) phthalate metabolite concentrations 
among the preterm women compared with 
controls. Variables considered in this analysis 
included maternal age, prepregnancy body 
mass index (BMI), parity, education, marital 
status, the infant’s sex, and gestational age at 
the time of urine sample collection. Variables 
that did not differ between cases and controls 
and did not statistically confound (change 
in effect estimate of > 10%) in any of the 
models were not retained. The variables that 
did appreciably change (> 10%) the effect 
estimate in at least one of the models were 
included in all models for consistency.
Results
Table 1 presents maternal and pregnancy 
characteristics of the 30 selected preterm cases 
and the 30 term controls. Cases and con-
trols did not differ by age, BMI, parity, or 
history of previous preterm deliveries. Cases 
and controls differed slightly with regard to 
marital status, education, and gestational age 
at the time the urine sample was collected. 
Table 2 presents distributions of uncorrected 
phthalate concentrations measured in urine 
of controls. Similar to recent U.S. stud-
ies, phthalate metabolites were detected in 
all samples. Among monoesters, the lower-
molecular-weight phthalate metabolites MBP 
and MEP had median values of 33.4 and 
108 µg/L, respectively. In comparison, the 
higher-molecular-weight monoester MBzP 
had a median concentration of 2.85 µg/L. 
Among DEHP metabolites, the oxidative 
metabolites MEOHP, MEHHP, and MECPP 
had median concentrations of 13.6, 17.1, and 
38.2 µg/L, respectively, which, consistent with 
previous reports (CDC 2005), were higher 
than that of the monoester MEHP (3.0 µg/L).
Table 1. Maternal and pregnancy characteristics for controls (term) and cases (preterm).
Characteristic
Term 
(≥ 37 weeks; n = 30)
Preterm 
(< 37 weeks; n = 30)
Maternal age (years) [median (25th, 75th percentile)] 27 (23, 30) 27 (23, 32)
Prepregnancy BMI [median (25th, 75th percentile)] 25 (22, 27) 25 (23, 28)
Weeks gestation at urine sample [median (25th, 75th percentile)] 34 (33, 35) 33 (32, 35)
Parity [no. (%)]
First child 10 (33) 10 (33)
Not first child 20 (67) 20 (67)
Previous preterm delivery [no. (%)] 
Yes 2 (7) 2 (7)
No 28 (93) 28 (93)
Marital status [no. (%)]
Married 20 (67) 17 (57)
Unmarried living with partner 6 (20) 7 (23)
Single 4 (13) 6 (20)
Maternal education [no. (%)]
< High school 17 (57) 15 (50)
≥ High school 13 (43) 15 (50)
Infant sex [no. (%)]
Male 15 (50) 13 (43)
Female 15 (50) 17 (57)Phthalates and preterm birth
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Correlations between phthalate metabo-
lites were moderate to strong. Spearman cor-
relation coefficients between metabolites from 
different parent diesters ranged from 0.21 
(between MEHP and MEP) to 0.68 (between 
MECPP and MCPP). The Spearman cor-
relation between MEHP and MBP was 0.44. 
Among the DEHP metabolites, Spearman 
correlations ranged from 0.80 to 0.84 
between MEHP and the oxidized metabo-
lites (MEHHP, MEOHP, and MECPP) and 
were ≥ 0.91 between the oxidized DEHP 
metabolites. Among metabolites of DBP, 
the Spearman correlation between MBP and 
MCPP was 0.85.
Table 3 presents crude results comparing 
phthalate metabolite concentrations between 
cases and controls for phthalate concentra-
tions that were uncorrected for urine dilu-
tion, SG corrected, and Cr corrected. When 
phthalates were uncorrected for dilution, 
concentrations of all metabolites detected in 
at least 80% of samples were higher among 
cases compared with controls, and concen-
trations for many metabolites among cases 
were nearly double those of controls. The larg-
est difference in uncorrected phthalate uri-
nary metabolites was observed with MBP, for 
which median concentrations of cases were 
3-fold higher than controls (p < 0.005). Cases 
had higher SG (p = 0.07) and Cr (p = 0.06) 
values than did controls, indicating that the 
urine samples of women who delivered at 
term were more diluted than samples from 
women who delivered preterm. These differ-
ences in urine dilution somewhat reduced the 
observed differences in phthalate metabolite 
concentrations after correcting by SG and Cr, 
but concentrations of all metabolites remained 
higher in cases than in controls.
Table 4 presents results from multivari-
able logistic regression analysis adjusted for 
potential confounding variables. Preterm birth 
cases had elevated odds for having phthalate 
metabolite concentrations above the median 
for all metabolites. For metabolite concentra-
tions uncorrected for dilution, the greatest odds 
ratios (ORs) and 95% confidence intervals 
(CIs) were observed for the DBP and diisobu-
tyl phthalate metabolites MBP (OR = 10.7; 
95% CI, 2.4–47.4), MiBP (3.6; 1.1–12.2), 
and MCPP (6.3; 1.8–21.9); for the DEHP 
metabolites MEHP (3.5; 1.0–12.9), MEHHP 
(4.6; 1.3–16.7), and MEOHP (7.1; 1.9–26.5); 
and for the sum of DEHP metabolites (5.0; 
1.4–18.0). Correction of metabolite concen-
trations by SG or Cr attenuated these ORs, 
although they remained elevated for most 
metabolites, particularly MBP and MEHP.
Discussion
We conducted a nested case–control analysis 
of Mexican mother–infant pairs and found evi-
dence for the presence of higher third-trimester 
urinary concentrations of phthalate metabolites 
among pregnant women who delivered pre-
term (< 37 weeks gestation) compared with 
women who delivered at term (≥ 37 weeks). 
The differences between cases and controls for 
DBP metabolites (MBP and MCPP; MCPP 
is an oxidative metabolite of DBP as well as a 
major metabolite of DOP) and MEHP were 
not sensitive to correction for urinary dilu-
tion using SG or Cr or to the adjustment for 
Table 2. Distribution of third-trimester urinary concentrations of phthalate metabolites (uncorrected for 
dilution) among 30 Mexican women who delivered ≥ 37 weeks of gestation (μg/L).
Phthalate 
metabolite % > LOD
Geometric 
mean
Percentile
25th 50th 75th 90th  95th  Maximum
MEHP 80 1.9 0.60 3.00  4.40 9.55 11.8 14.1
MEHHP 100 13.6 6.20 17.1  28.4 65.7 91.5 129
MEOHP 100 10.4 5.00 13.6  24.5 49.6 74.2 101
MECPP 100 29.7 14.3 38.2 53.8 135 160 173
MBzP 92 2.3 1.00 2.85  5.20 16.8 20.2 23.3
MBP 100 38.1 21.3 33.4  74.0 198 355 557
MiBP 97 1.9 0.80 2.00 4.10 8.80 13.1 58.5
MCPP 95 1.1 0.50 1.25 2.00 4.10 5.10 9.80
MCOP 67 NC < LOD 0.80  1.20 2.70 3.70 4.90
MCNP 67 NC < LOD 0.85  1.20 1.80 2.40 2.80
MEP 100 112 47.1 108 224 740 897 4,750
Sum DEHPa — 0.19 0.09 0.24  0.38 0.86 1.14 1.34
NC, not calculated because of high proportion (33%) of samples < LOD (0.7 μg/L for MCOP and 0.6 μg/L for MCNP).
anmol/L.
Table 3. Geometric mean and median third-trimester urinary phthalate metabolite concentrations among 
women who had term or preterm births.
Phthalate metabolite
Geometric mean Median (25th, 75th percentile)
p-Valuea Term (n = 30) Preterm (n = 30) Term (n = 30) Preterm (n = 30)
Uncorrected (μg/L)
MEHP 1.9 3.5 3.0 (0.3, 4.4) 4.3 (2.2, 7.1) 0.05
MEHHP 13.6 24.0 17.1 (6.2, 28.4) 28.7 (18.1, 37.5) 0.04
MEOHP 10.4 18.9 13.6 (5.0, 24.5) 20.8 (14.4, 25.5) 0.04
MECPP 29.7 51.2 38.2 (14.3, 53.8) 55.2 (39.2, 73.3) 0.02
MBzP 2.3 5.2 2.9 (1.0, 5.2) 5.4 (2.6, 9.5) 0.01
MBP 38.1 89.9 33.4 (21.3, 74.0) 97.1 (56.0, 139) 0.005
MiBP 1.9 3.1 2.0 (0.8, 4.1) 3.3 (2.2, 5.1) 0.08
MCPP 1.1 2.4 1.3 (0.5, 2.0) 2.3 (1.1, 4.9) 0.002
MCOP NC NC 0.80 (< LOD, 1.2) 1.2 (< LOD, 1.7) NC
MCNP NC NC 0.85 (< LOD, 1.2) 0.90 (< LOD, 1.6) NC
MEP 112 204 108 (47.1, 224) 171 (69.4, 437) 0.10
Sum DEHP metabolism 0.19 0.33 0.24 (0.09, 0.38) 0.37 (0.23, 0.45) 0.03
SG corrected (μg/L)
MEHP 2.5 3.6 3.0 (1.1, 5.9) 4.3 (2.6, 6.2) 0.15
MEHHP 18.1 24.5 21.3 (9.3, 31.4) 25.7 (17.2, 31.4) 0.14
MEOHP 13.9 19.3 15.5 (7.8, 29.0) 20.1 (14.4, 23.8) 0.11
MECPP 39.5 52.4 37.1 (22.4, 65.2) 56.7 (38.8, 72.8) 0.09
MBzP 3.1 5.3 3.2 (1.5, 7.8) 6.5 (3.5, 9.8) 0.05
MBP 50.7 92.0 52.4 (28.4, 101) 88.1 (58.6, 148) 0.01
MiBP 2.5 3.2 2.3 (1.1, 5.0) 3.3 (1.9) 0.3
MCPP 1.4 2.4 1.6 (0.7, 2.6) 2.3 (1.4, 4.1) 0.009
MCOP NC NC 0.49 (< LOD, 1.3) 1.0 (< LOD, 1.5) NC
MCNP NC NC 0.86 (< LOD, 1.4) 0.91 (< LOD, 1.3) NC
MEP 150 209 134 (45.2, 284) 182 (68.3, 340) 0.3
Sum DEHP metabolism 0.25 0.34 0.27 (0.13, 0.44) 0.37 (0.24, 0.42) 0.11
Cr corrected (μg/g Cr)
MEHP 3.3 4.7 3.7 (1.7, 7.4) 5.6 (3.3, 7.4) 0.18
MEHHP 24.1 32.1 23.0 (11.4, 52.1) 33.2 (24.1, 41.5) 0.17
MEOHP 18.5 25.3 19.0 (9.5, 42.1) 24.5 (20.6, 29.2) 0.14
MECPP 52.8 68.5 48.0 (27.3, 98.6) 71.1 (52.7, 77.4) 0.10
MBzP 4.1 7.0 4.6 (2.2, 9.1) 8.7 (4.1, 11.7) 0.05
MBP 67.8 120 63.1 (34.8, 176) 127 (81.4, 171) 0.01
MiBP 3.3 4.2 3.7 (1.3, 6.6) 4.1 (2.3, 7.9) 0.3
MCPP 1.9 3.2 1.9 (1.0, 3.2) 2.9 (1.9, 5.3) 0.007
MCOP NC NC 0.68 (< LOD, 1.8) 0.90 (< LOD, 1.7) NC
MCNP NC NC 1.2 (< LOD, 1.7) 1.1 (< LOD, 1.5) NC
MEP 200 274 186 (64, 401) 232 (106, 396) 0.3
Sum DEHP metabolism 0.34 0.44 0.26 (0.16, 0.55) 0.36 (0.28, 0.45) 0.13
NC, not calculated because of high proportion (33%) of samples < LOD.
aTwo-tailed Student’s t-test of ln-transformed phthalate metabolite concentrations.Meeker et al.
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potential confounding variables. These results 
provide the first evidence of an association 
between phthalate exposure during pregnancy 
and preterm birth.
Our findings of higher DEHP metabo-
lite concentrations (MEHP and the oxida-
tive metabolites MEOHP, MEHHP, and 
MECPP) among mothers delivering pre-
term are consistent with an Italian study of 
84 newborns that reported an inverse asso-
ciation between gestational age and DEHP 
exposure (Latini et al. 2003). In that study, 
MEHP (but not DEHP) in the cord blood of 
the newborns was associated with decreased 
gestational age at delivery (OR for absence 
of detectable MEHP in cord blood associ-
ated with a 1-week increase in gestational age 
= 1.50; 95% CI, 1.01–2.21), and the mean 
gestational age among infants with MEHP 
detected in cord blood was 1.2 weeks (8.4 
days) less than that of infants with nonde-
tectable MEHP in cord blood (p = 0.03). 
However, there are uncertainties over the use 
of cord blood to measure phthalates in the 
study, because blood measures of phthalate 
exposure can be compromised because of con-
tamination by phthalate diesters in sampling 
tubes and lipases in the blood that can convert 
the diesters to monoesters (Kato et al. 2003).
Our finding that DEHP metabolites were 
elevated in mothers delivering preterm is also 
consistent with a recent study of 331 African-
American and Dominican mothers and new-
borns in New York City (Whyatt et al. 2008). 
In that study, women with third-trimester spot 
urine samples with SG-corrected MEHP con-
centrations in the highest quartile delivered 
infants with gestational ages 5.1 days (95% 
CI, 2.1–8.4 days) less than did women in the 
lowest MEHP quartile (p < 0.001). In con-
trast, our results are inconsistent with another 
recent study of third-trimester urines from 404 
women in a multiethnic birth cohort from 
New York City, which reported increased 
gestational ages in relation to MEHP and the 
sum of MBP, MEP, and MiBP concentra-
tions (Wolff et al. 2008). Differences between 
the results of the two New York City stud-
ies and between our study and the study by 
Wolff et al. (2008) may reflect differences in 
study designs, population characteristics (e.g., 
age, ethnicity, education, and quality of care), 
exclusion criteria, and/or exposure levels or 
sources. Moreover, gestation length, but not 
preterm birth, was assessed in these previous 
epidemiologic studies of phthalates and birth 
outcomes.
There were some differences in phthalate 
metabolite concentrations among pregnant 
women who delivered at ≥ 37 weeks in our 
Mexican cohort compared with those reported 
in the 2001–2002 National Health and 
Nutrition Examination Survey for women in 
the United States (Adibi et al. 2008; CDC 
2005). The median MBP concentration uncor-
rected for urine dilution was 2-fold higher in 
our Mexican cohort than in females from the 
U.S. population, and the Cr-corrected MBP 
median was 3-fold higher. Conversely, median 
MBzP concentrations were about 4-fold lower 
in the present study compared with U.S. 
females for uncorrected and Cr-corrected 
concentrations. Median uncorrected MEHP, 
MEHHP, MEOHP, MiBP, MCPP, and MEP 
concentrations were comparable between the 
two populations, although somewhat lower 
among women in the present study. The pres-
ence of similar to slightly lower MiBP con-
centrations but higher MBP concentrations 
in this Mexican population suggests potential 
differences in patterns or sources of exposure to 
dibutyl phthalates compared with U.S. women. 
Based on our preliminary exposure results 
and evidence for adverse effects of DBP and/
or MBP on fetal development (Foster 2006; 
Swan 2008), research designed to assess sources 
of DBP exposure among pregnant Mexican 
women is warranted.
Compared with controls, women who 
had preterm births in the present study had 
suggestively higher levels of urinary Cr [and 
SG, because the two were highly correlated 
(Spearman r = 0.9)], which served to lessen 
the differences in phthalate metabolite con-
centrations after correcting for SG or Cr. Cr 
clearance increases significantly during preg-
nancy, in a manner that peaks and then begins 
to decline several weeks before term (Boeniger 
et al. 2003; Davison et al. 1980; Lohsiriwat 
and Imrittha 2008; Sims and Krantz 1958). 
There is variability in the magnitude and tim-
ing of the peaks (as well as the slope of the 
subsequent decline in Cr clearance) among 
women (Davison et al. 1980; Sims and Krantz 
1958), and it may not be appropriate to cor-
rect third-trimester urinary phthalate metabo-
lite concentrations by Cr (Adibi et al. 2008). 
It is possible that the higher Cr levels among 
cases may be related to an unmeasured risk 
factor for preterm birth, but to our knowl-
edge the ability of urinary Cr to predict pre-
term birth has not been previously reported. 
In addition to fluctuations in Cr clearance 
during pregnancy, there are also cyclic within-
woman fluctuations in Cr clearance in relation 
to normal menstrual cycles that are poten-
tially caused by changes in hormone activity 
(Davisonand Nobles 1981). Thus, it may also 
be possible that increased urinary Cr levels 
could be related to phthalate-induced altera-
tions in endocrine function, although there are 
currently no data to support this hypothesis.
Preterm birth is likely a syndrome with 
multiple etiologies (Goldenberg et al. 2008). 
Although there is no clear explanation at 
this time for an association between phtha-
late exposure and preterm birth, several plau-
sible hypotheses may be put forth. Among 
the various risk factors identified for preterm 
birth, maternal inflammation, particularly 
chorioamnionitis, has been firmly linked to 
preterm birth in epidemiologic and labora-
tory studies (Romero et al. 2007). Because 
phthalate metabolites stimulate proinflamma-
tory responses in cells in culture, including 
cytokine release (Jepsen et al. 2004), activa-
tion of the mitogen-activated protein kinase 
pathway (Pauley et al. 2002), and activation 
of the peroxisome proliferator-activated recep-
tor (PPAR)-α and PPAR-γ pathways (in a 
rat placental trophoblast cell line) (Xu et al. 
2005), phthalate exposure may increase risk 
for preterm birth if it stimulates an inflam-
matory response in pregnant women, as pro-
posed previously (Latini et al. 2005, 2006). 
Additionally, prostaglandins are important sig-
naling molecules in parturition, and phthalate 
metabolites increase expression of prostaglan-
din-endoperoxide synthase 2 (PTGS2, also 
known as COX-2) in a rat placental tropho-
blast cell line (Xu et al. 2005) and mouse liver 
cells (Ledwith et al. 1997). Because PTGS2 
is necessary for synthesis of prostaglandins, 
phthalate-stimulated induction of PTGS2 in 
Table 4. Adjusteda ORs for high (> median) third-trimester urinary phthalate metabolite concentrations 
(unadjusted, SG corrected, and Cr corrected) among women who delivered preterm compared with 
controls.
Phthalate 
metabolite
Unadjusted (μg/L) SG corrected (μg/L) Cr corrected (μg/g Cr)
n1 n2 OR (95% CI) n1 n2 OR (95% CI) n1 n2 OR (95% CI)
MEHP 18 12 3.5 (1.0–12.9) 18 12 3.2 (0.9–11.3) 18 12 3.2 (0.9–11.3)
MEHHP 19 11 4.6 (1.3–16.7) 15 15 0.9 (0.3–3.1) 17 13 2.9 (0.8–10.8)
MEOHP 20 10 7.1 (19–26.5) 17 13 1.9 (0.6–6.5) 17 13 3.2 (0.9–11.0)
MECPP 18 12 2.8 (0.9–9.3) 18 12 3.4 (1.0–12.0) 17 13 2.9 (0.8–11.0)
MBzP 18 12 2.5 (0.8–8.5) 18 12 2.2 (0.7–6.7) 12 12 2.2 (0.7–6.7)
MBP 20 10 10.7 (2.4–47.4) 19 11 4.5 (1.2–16.6) 20 10 5.4 (1.5–19.3)
MiBP 19 11 3.6 (1.1–12.2) 17 13 2.0 (0.7–6.0) 16 14 1.5 (0.5–4.5)
MCPP 21 9 6.3 (1.8–21.9) 19 11 3.2 (1.0–9.8) 18 12 3.0 (0.9–10.0)
MCOP 19 11 4.3 (1.2–14.9) 16 14 1.3 (0.5–3.9) 17 13 2.0 (0.7–6.0)
MCNP 18 12 1.3 (0.4–4.0) 15 15 1.2 (0.4–3.6) 15 15 1.2 (0.4–3.6)
MEP 18 12 2.3 (0.7–7.3) 16 14 1.3 (0.4–4.2) 16 14 1.3 (0.4–4.1)
Sum DEHP  19 11 5.0 (1.4–18.0) 17 13 1.9 (0.6–6.5) 17 13 4.1 (1.0–17.5)
Abbreviations: n1, number of cases with high (> median) urinary phthalate concentration; n 2, number of controls with 
high (> median) urinary phthalate concentration.
aAdjusted for marital status, maternal education, infant sex, and gestational age at time of urine sample.Phthalates and preterm birth
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gestational tissues such as placenta and the 
extraplacental membranes could increase 
risk for preterm birth by increasing prema-
ture intrauterine production of prostaglan-
dins. Alternatively, matrix metalloproteinases 
(MMPs) are activated by inflammatory cytok-
ines, and MEHP activates an MMP in rat tes-
tis (Yao et al. 2009). If phthalate metabolites 
activate MMPs in extraplacental membranes, 
it could lead to preterm premature rupture of 
the membranes (PPROM) and preterm birth.
In addition to inflammation, increased 
apoptosis in the maternal/fetal membranes is 
associated with PPROM as well as membrane 
rupture at term (Kataoka et al. 2002; Reti et al. 
2007). MEHP stimulates cell responses that 
can initiate apoptosis, including DNA damage 
(in human sperm) (Hauser et al. 2007), oxida-
tive stress (in the testes) (Kasahara et al. 2002), 
release of cytochrome c from mitochondria 
(Kasahara et al. 2002), and increased expres-
sion of Fas ligand, an apoptosis-initiating pro-
tein (Richburg and Boekelheide 1996; Yao 
et al. 2007). Oxidative stress is also believed 
to be involved in the developmental toxic-
ity of DBP (Kim et al. 2002; Wellejus et al. 
2002). However, most studies of phthalate 
metabolite–stimulated oxidative stress, DNA 
damage, and apoptosis have been conducted 
in males, and studies of effects in females and 
on pregnancy outcomes are needed.
Alternate mechanisms could involve 
phthalate impacts on endocrine function. The 
phthalate diesters DEHP, DBP, and BBzP, 
and/or their metabolites, are antiandrogenic in 
males (Foster 2006; Meeker et al. 2008; Swan 
2008) and have been shown to reduce estradiol 
and progesterone production in female rodents 
and in rat granulosa cells in vitro (Gray et al. 
2006; Lovekamp and Davis 2003; Treinen 
et al. 1990). Because progesterone plays a key 
role in maintaining uterine quiescence during 
pregnancy, it may be plausible that phthalates 
alter the timing of labor by reducing proges-
terone production. Furthermore, estradiol is 
vital in suppressing inflammation and oxida-
tive stress (Straub 2007; Vina et al. 2006). 
However, data in support of the pathways pro-
posed here involving endocrine disturbances, 
inflammation, and oxidative stress are lacking, 
and additional research is needed to explore 
these potential mechanisms.
The present study has several limitations, 
including its relatively small size, the inability 
to study high-risk preterm births occurring 
more remote from term, and the potential 
for misclassification stemming from mater-
nal recall of last menstrual period to estimate 
gestational age. Misclassification of preterm 
cases may be nondifferential with respect to 
exposure status. However, we cannot rule 
out differential misclassification. For exam-
ple, although there is currently no evidence 
in support of this hypothesized scenario, if 
phthalate exposure was associated with altered 
menstrual cycle length, it may have resulted 
in systematic underestimates of last menstrual 
period and gestational age among highly 
exposed women. Another limitation of our 
study is the potential for uncontrolled biases 
due to the 1-week difference in median ges-
tational age at the time of urine sample col-
lection between cases and controls. However, 
although this sample timing was associated 
with case status, and statistically confounded 
at least one of the multivariable models and 
thus was included in the adjusted ORs pre-
sented in Table 4, it was not associated with 
uncorrected or dilution-corrected urinary 
phthalate metabolite concentrations. Our 
study also made a large number of statistical 
comparisons, which may have led to chance 
findings of statistical significance. In addition, 
the potential for reverse causation cannot be 
ruled out, whereby other underlying risk fac-
tors for delivering preterm could be associated 
with increased phthalate exposure or altered 
phthalate metabolism. Finally, our ability to 
interpret these results to determine which spe-
cific phthalates or phthalate metabolites may 
be the most relevant to preterm birth risk was 
limited because concentrations of many com-
pounds were higher among preterm cases and 
the various phthalate metabolites were moder-
ately to strongly correlated with one another.
In conclusion, the present study provides 
evidence for a potential role for phthalate expo-
sure (DBP, DOP, DEHP, and/or BBzP) in pre-
term birth among a group of Mexican women. 
Additional research, including larger human 
studies and experimental studies, are warranted 
to further investigate the relationship between 
phthalate exposure and preterm birth.
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